UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/030,294	12/27/2001	Toshiyuki Sakai	442P090	9019

7590 11/23/2004

Nields Lemack & Dingman
176 E Main Street Suite 8
Westboro, MA 01581

EXAMINER	
YU, MISOOK	
ART UNIT	**PAPER NUMBER**
1642	

DATE MAILED: 11/23/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/030,294	SAKAI ET AL.	
	Examiner	Art Unit	
	MISOOK YU, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *07 September 2004*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1-5* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1-5* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date *3/12/02*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☒ Other: *Exhibits A and B*.

DETAILED ACTION

Election/Restrictions

Applicant's election of group I in the reply filed on 9/7/2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). All non-elected claims are cancelled. Claims 1-5 are pending and examined on merits.

Information Disclosure Statement

The information disclosure statement filed 03/12/2002 contains two WO documents, i.e. WO 99/50412, and WO 99/61610 that are in Japanese and German respectively. It is noted that both documents are cited in the ISR. The English translation of the entire texts have not been submitted, therefore both documents have been considered to the extent (abstract, sequence listings, and some drawings) that the Examiner could understand.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-5 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, and 2 recite "under a stringent condition" but it is clear what the metes and bounds are. All dependent claims are also rejected because the scope

encompassed by the dependent claims includes the hybridizing molecules under the unclear conditions.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-5 are interpreted as drawn to as a gene, and genus of nucleic acids encoding p51 5'untranslated region, wherein said gene or genus is in a recombinant plasmid (claim 3), in a transformant (claim 4).

The applicable standard for the written description requirement can be found: MPEP 2163; University of California v. Eli Lilly, 43 USPQ2d 1398 at 1407; PTO Written Description Guidelines; Enzo Biochem Inc. v. Gen-Prove Inc., 63 USPQ2d 1609; Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111; and University of Rochester v. G.D. Searle & Co., 69 USPQ2d 1886 (CA FC 2004).

First, the base claims 1 as currently construed reads on the entire p51 gene comprising SEQ ID NO:2 plus an native enhancer region controlling the transcription of said coding region because Darnell et al., (1990, Molecular Cell Biology, 2nd Edition,

pages 344-345 only) teach that a gene also includes enhancer. However, the specification does not disclose any enhancer element of p51 gene.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claim 2 is partial structure in form of mutations, and/or hybridization under an unclear hybridization condition. There is not even identification of any particular portion of the structure that must be conserved in order to have the recited function. Further, claim 2 does not say the identity of the function. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed.*" (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of nucleic acid molecules, given that the specification has only

described SEQ ID NO: 1 and 2 (note SEQ ID NO:2 is a slightly longer than SEQ ID NO:1, otherwise identical). Therefore, only isolated nucleic acid comprising SEQ ID NO:1 and 2, but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

> Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1, 2, and 5 are rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter.

Claims 1, 2, and 5, as written, do not sufficiently distinguish over nucleic acids, as they exist naturally because the claims do not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of "Isolated" or "Purified". See MPEP 2105.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 3, 4, and 5 are rejected under 35 U.S.C. 102(b) as being anticipated by GenBank Acc. No. AQ168656 (16 October, 1998).

The claims are broadly interpreted as drawn to a nucleic acid sequence with various degrees of sequence similarities to either SEQ ID NO:1, or 2 (claim 1) or to specific portion of SEQ ID NO:2 (claim 2), wherein the claimed nucleic acid has p51 promoter activity (claim 1), or an undefined activity of the specific portion of SEQ ID NO:2 (claim 2), wherein a recombinant plasmid (claim 3), a transformant (claim 4), a nucleic acid probe (claim 5) are claimed.

GenBank Acc. No. AQ168656 teach a nucleic acid with 90.6 % similarity from nucleotide #672 to 1171 of instant SEQ ID NO:2 (note Exhibit A), and also teaches that the clone is in plasmid vector pBeloAAC11, which is a BAC cone in E. Coli strain DH10B. Thus, the strain of E. coli is a transformant. Since both claims 1, and 2 do not specify how many nucleic acid could be deleted, substituted, or added in the base sequence in SEQ ID NO:1, or the specific portion of SEQ ID NO:2 (note for example the claim construction of claim 1 (2), or claim 2 (8)), the scope is broadly interpreted as all of base deleted, substituted, and/or added. Therefore, it is concluded that the nucleic acid sequence of GenBank Acc. No. AQ168656 meets the structural imitation of the claimed nucleic acid. As for whether the nucleic acid of the art has either p51 promoter activity or has the unspecified function of the specific portion of SEQ ID NO:2, the Office does not have the facilities and resources to provide the factual evidence needed in order to establish that the nucleic acid of possess the same functional characteristics of the instantly claimed nucleic acid. In the absence of evidence to the contrary, the

burden is on the applicant to prove that the claimed nucleic acid (especially in claim 1 (2), and (5)) is different from those taught by the prior art and to establish patentable differences. See In re Best 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989). Furthermore, the preamble recitation of probe in claim 5 is merely suggestive of an intended use and is not given patentable weight for purposes of comparing the claim with the prior art. The claim reads on the nucleic acid *per se*.

Claims 1, 2, and 5 are rejected under 35 U.S.C. **102(b)** as being anticipated by Yang et al., (1998, Molecular Cell, vol. 2, pages 305-316).

The claims are broadly interpreted as drawn to a nucleic acid sequence with various degrees of sequence similarities to either SEQ ID NO:1, or 2 (claim 1) or to specific portion of SEQ ID NO:2 (claim 2), wherein the claimed nucleic acid has related p51 promoter activity (claim 1), or an undefined activity of the specific portion of SEQ ID NO:2 (claim 2), a nucleic acid probe (claim 5) are claimed.

Yang et al., at Fig. 2A teach a genomic structure of p63 gene encoding at least 6 different splicing variants. It appears that p51 gene is same as p63 gene because GenBank Acc. No. AF124528 (Jan. 04, 2001) teaches that the C-terminal end of instant SEQ ID NO:2, more specifically nucleotides #5462 to #5960 of SEQ ID NO:2 is exon 1 of p63 (note Exhibit B) shown in Fig. 2A of Yang et al. Yang et al., at page 314 under the heading "Cloning of p63" teaches a 120 kb clone that contains all of the human p63 gene, also teach at page 308, right column "the human p63 PAC clone as a probe" is

used to map the gene to 3q27-29 (note also Fig. 3). Although Yang et al., do not list the nucleic acid sequence of the instant claimed promoter and/or 5' untranslated region sequence, it appears that the instantly claimed gene sequence and the sequence of p63 of the art are same. The court, especially Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989) stated that in order to be the same product, the art does not have to list the chemical composition of the product. Here, the human 120 kb clone used to map the p63 gene to 3q27-29 (note Fig. 3) appear to contain all of instantly claimed p51 gene including the promoter region, or the 5'-untranslated region. The Office does not have the facilities and resources to provide the factual evidence needed in order to establish that the nucleic acid of possess the same functional characteristics of the instantly claimed nucleic acid. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed nucleic acid (especially in claim 1 (2), and (5)) is different from those taught by the prior art and to establish patentable differences. See In re Best 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989). Furthermore, the preamble recitation of probe in claim 5 is merely suggestive of an intended use and is not given patentable weight for purposes of comparing the claim with the prior art. The claim reads on the nucleic acid *per se*.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU, Ph.D. whose telephone number is 571-

272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey C Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

MISOOK YU, Ph.D.
Examiner
Art Unit 1642

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: September 27, 2004, 07:46:34 ; Search time 13713 Seconds
(without alignments)
12978.823 Million cell updates/sec

Title: US-10-030-294-2
Perfect score: 5960
Sequence: 1 cagctgttcagggatgtctg.....ttttggttgatatttggatc 5960

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_phg:*
27: em_gss_vrl:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	427.8	7.2	523	28	AQ168656	AQ168656 HS_3165_B
	2	378.2	6.3	638	13	BY723946	BY723946 BY723946
	3	280.4	4.7	293	12	BG212218	BG212218 RST31802
c	4	267	4.5	288	12	BG219090	BG219090 RST38843
c	5	262	4.4	277	12	BG212753	BG212753 RST32348
	6	184.6	3.1	567	12	BI497128	BI497128 df132c05.
c	7	181.6	3.0	664	28	AQ275866	AQ275866 CITBI-E1-
	8	180.6	3.0	725	28	CC061176	CC061176 MUGQ_CH25
	9	180	3.0	828	28	BZ601705	BZ601705 WHABF61TR
	10	179.8	3.0	733	28	AQ052879	AQ052879 RPCI11-42
	11	179.6	3.0	567	13	BQ691256	BQ691256 AGENCOURT
	12	179.6	3.0	810	28	AQ780966	AQ780966 HS_3138_B
	13	179	3.0	637	13	BQ688837	BQ688837 AGENCOURT
c	14	178.8	3.0	440	9	AI362915	AI362915 qy81c06.x
c	15	178.2	3.0	674	29	AG073447	AG073447 Pan trogl
	16	178	3.0	463	13	BQ883640	BQ883640 AGENCOURT
c	17	177.8	3.0	449	9	AI365624	AI365624 ap20e10.x
	18	177.6	3.0	680	28	AQ750933	AQ750933 HS_5574_B
	19	177.6	3.0	1025	12	BM907570	BM907570 AGENCOURT
	20	176	3.0	680	28	AQ046675	AQ046675 RPCI11-42
c	21	176	3.0	706	12	BM701690	BM701690 UI-E-CQ1-
	22	175.4	2.9	330	9	AA226173	AA226173 nc11g08.s
c	23	175	2.9	917	13	BU153359	BU153359 AGENCOURT
	24	174.2	2.9	657	28	AQ343025	AQ343025 RPCI11-12
	25	174.2	2.9	834	28	AQ749761	AQ749761 HS_5573_A
	26	174	2.9	490	14	CA395712	CA395712 cs68a08.y
c	27	173.6	2.9	360	9	AI167878	AI167878 oz91b12.x
c	28	173.4	2.9	677	14	CA307465	CA307465 UI-H-FT1-
	29	173.2	2.9	6069	11	BC036681	BC036681 Homo sapi
c	30	172.8	2.9	532	28	CC061208	CC061208 MUGQ_CH25
	31	172.4	2.9	589	10	BE562634	BE562634 601336472
c	32	172.2	2.9	693	29	AG087187	AG087187 Pan trogl
	33	172	2.9	549	14	W07317	W07317 za94b10.r1
c	34	171.8	2.9	416	9	AA715814	AA715814 nw25c01.s
	35	171.6	2.9	409	28	AQ413740	AQ413740 RPCI-11-2
	36	171.6	2.9	586	28	AQ038047	AQ038047 CIT-HSP-2
c	37	171.6	2.9	1201	9	AL543301	AL543301 AL543301
	38	171.4	2.9	729	12	BG536633	BG536633 602566240
	39	171.4	2.9	1155	12	BM563733	BM563733 AGENCOURT
c	40	171.2	2.9	456	14	D44625	D44625 HUMSUPY023
c	41	171.2	2.9	491	28	AQ729774	AQ729774 HS_2133_A
c	42	171	2.9	535	28	AQ623103	AQ623103 HS_5354_A
	43	171	2.9	694	28	BZ603010	BZ603010 WHAAX35TF
c	44	170.8	2.9	394	28	AQ803962	AQ803962 HS_2005_A
	45	170.6	2.9	826	12	BG764269	BG764269 602736143

ALIGNMENTS

RESULT 1
AQ168656
LOCUS AQ168656 523 bp DNA linear GSS 16-OCT-1998
DEFINITION HS_3165_B2_F08_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3165 Col=16 Row=L, genomic survey sequence.
ACCESSION AQ168656
VERSION AQ168656.1 GI:3566331
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 523)
AUTHORS Mahairas,G.G., Wallace,J.C., Smith,K., Swartzell,S., Holzman,T., Keller,A., Shaker,R., Furlong,J., Young,J., Zhao,S., Adams,M.D. and Hood,L.
TITLE Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)
MEDLINE 99380589
PUBMED 10449764
COMMENT Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618

Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 3165 row: L column: 16
Class: BAC ends
High quality sequence stop: 523.

FEATURES Location/Qualifiers
source 1. .523
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=3165 Col=16 Row=L"
/sex="male"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/note="Organ: sperm; Vector: pBeloBAC11; BAC Clones in E-Coli DH10B"

ORIGIN

Query Match 7.2%; Score 427.8; DB 28; Length 523;
Best Local Similarity 90.6%; Pred. No. 6.9e-52;
Matches 453; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

```
Qy       672 GATCTCATAGTCACAGGCTGCCAGAGCTCTACGGAACATGCAAGATCATCTGCTTTAAGC 731
Db        12 GANTCTNTAAGTACGNGATGAATTCGATCTACGGAACATGCAAGATCATCTGCTNTAAGC  71

Qy       732 CTCTTGTGGTGGCATCTGTTGTTTTCCACTGCCCTGTACCTATTGCTCTTTCCTTGGTTA 791
Db        72 CTCTTGTGGTGGCATCTGTTGTTTTCCACTGCCCTGTACCTATTGCTCTTTCCTTGGTTA 131

Qy       792 ACAGAACCTTTATTTTCTTCTGAAAACTCTCTGCTCAGTCATGGTAGGGCCATCAGTCCA 851
Db       132 ACAGAACCTTTATTTTCTTCTGAAAACTCTCTGCTCAGTCATGGTAGGGCCATCAGTCCA 191

Qy       852 CATGATCAGGCCTCTCCTGGCCAAACATGGCATCTTTCTTTTGGGAATTTGAATCTTAAG 911
Db       192 CATGATCAGGCCTCTCCTGGCCAAACATGGCATCTTTCTTTTGGGAATTTGAATCTTAAG 251

Qy       912 CTGAATAGCTGAAGTTCAAAAAAAGCTGTTGAATCTGACTTACGCCTACAGTGGCTTTGC 971
Db       252 CTGAATAGCTGAAGTTCAAAAAAAGCTGTTGAATCTGACTTACGCCTACAGTGGCTTTGC 311

Qy       972 AAAGTGACTGTCCATTCCTATTTCTTAAGTCCCTGAATTTATAATTTATCCTGGTTACAG 1031
Db       312 AAAGTGACTGTCCATTCCTATTTCTTAAGTCCCTGAATTTATAATTTATCCTGGGTACAG 371

Qy      1032 CCCTTTCTGAGATGTGTGGTTTTTTTTCCAACTGTCTCTTATAGTCTGTGAATTTTCATA 1091
Db       372 CCCTTTCTGAGATGTGTGGATGTTTTTCCAACTGTCTCTTATAGTCTGAGAATTATCATA 431

Qy      1092 TTTCTTTTCATACATTTTCATGTTTTGTTTGTTTGTTTGTGTGTTTTTTGGCTTTAGGTA 1151
Db       432 TTTCTTTTCATACATTCTCATGCTGTGTTTGTTTGTCCGTGATGNTGTCAGACTTAAGTA 491

Qy      1152 GGCAGAATCAGTTTCTGTTG 1171
Db       492 GAAAGAATGGATCTATTCTG 511
```

RESULT 2
BY723946
LOCUS BY723946 638 bp mRNA linear EST 17-DEC-2002
DEFINITION BY723946 RIKEN full-length enriched, adult male hypothalamus Mus musculus cDNA clone A230061P11 5', mRNA sequence.
ACCESSION BY723946
VERSION BY723946.1 GI:27137063
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 638)
AUTHORS Okazaki,Y., Furuno,M., Kasukawa,T., Adachi,J., Bono,H., Kondo,S., Nikaido,I., Osato,N., Saito,R., Suzuki,H., Yamanaka,I., Kiyosawa,H., Yagi,K., Tomaru,Y., Hasegawa,Y., Nogami,A., Schonbach,C., Gojobori,T., Baldarelli,R., Hill,D.P., Bult,C., Hume,D.A., Quackenbush,J., Schriml,L.M., Kanapin,A., Matsuda,H., Batalov,S., Beisel,K.W., Blake,J.A., Bradt,D., Brusic,V., Chothia,C., Corbani,L.E., Cousins,S., Dalla,E., Dragani,T.A., Fletcher,C.F., Forrest,A., Frazer,K.S., Gaasterland,T., Gariboldi,M., Gissi,C., Godzik,A., Gough,J., Grimmond,S., Gustincich,S., Hirokawa,N., Jackson,I.J., Jarvis,E.D., Kanai,A., Kawaji,H., Kawasawa,Y., Kedzierski,R.M., King,B.L., Konagaya,A., Kurochkin,I.V., Lee,Y., Lenhard,B., Lyons,P.A., Maglott,D.R., Maltais,L., Marchionni,L., McKenzie,L., Miki,H., Nagashima,T., Numata,K., Okido,T., Pavan,W.J., Pertea,G., Pesole,G., Petrovsky,N., Pillai,R., Pontius,J.U., Qi,D., Ramachandran,S., Ravasi,T., Reed,J.C., Reed,D.J., Reid,J., Ring,B.Z., Ringwald,M., Sandelin,A., Schneider,C., Semple,C.A., Setou,M., Shimada,K., Sultana,R., Takenaka,Y., Taylor,M.S., Teasdale,R.D., Tomita,M., Verardo,R., Wagner,L., Wahlestedt,C., Wang,Y., Watanabe,Y., Wells,C., Wilming,L.G., Wynshaw-Boris,A., Yanagisawa,M., Yang,I., Yang,L., Yuan,Z., Zavolan,M., Zhu,Y., Zimmer,A., Carninci,P., Hayatsu,N., Hirozane-Kishikawa,T., Konno,H., Nakamura,M., Sakazume,N., Sato,K., Shiraki,T., Waki,K., Kawai,J., Aizawa,K., Arakawa,T., Fukuda,S., Hara,A., Hashizume,W., Imotani,K., Ishii,Y., Itoh,M., Kagawa,I., Miyazaki,A., Sakai,K., Sasaki,D., Shibata,K., Shinagawa,A., Yasunishi,A., Yoshino,M., Waterston,R., Lander,E.S., Rogers,J., Birney,E. and Hayashizaki,Y.
TITLE Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
JOURNAL Nature 420, 563-573 (2002)
MEDLINE 22354683
PUBMED 12466851
COMMENT Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@gsc.riken.go.jp,
URL:http://genome.gsc.riken.go.jp/
Adachi,J., Aizawa,K., Akimura,T., Arakawa,T., Carninci,P., Fukuda,S., Hashizume,W., Hayashida,K., Hirozane,T., Hori,F., Imotani,K., Ishii,Y., Itoh,M., Kagawa,I., Kawai,J., Kojima,Y., Kondo,S., Konno,H., Koya,S., Miyazaki,A., Murata,M., Nakamura,M., Nomura,K., Numazaki,R., Ohno,M., Ohsato,N., Saito,R., Sakazume,N., Sano,H., Sasaki,D., Sato,K., Shibata,K., Shiraki,T., Tagami,M., Takeda,Y., Waki,K., Watahiki,A., Muramatsu,M. and Hayashizaki,Y.
Direct Submission
Computational Analysis of Full-Length Mouse cDNAs Compared with Human Genome Sequences Mamm. Genome. 12, 673-677 (2001)
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. 10 (10), 1617-1630 (2000)
RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer. Genome Res. 10 (11), 1757-1771 (2000)
Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)
cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.
Please visit our web site (http://genome.gsc.riken.go.jp) for further details.

FEATURES Location/Qualifiers
source 1. .638
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="A230061P11"
/sex="male"





RESULT 11
HSP63G01
LOCUS HSP63G01 835 bp DNA linear PRI 04-JAN-2001
DEFINITION Homo sapiens P63 protein (P63) gene, exon 1.
ACCESSION AF124528

```
VERSION     AF124528.1  GI:12024731
KEYWORDS    .
SEGMENT     1 of 13
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 835)
  AUTHORS   Yang,A., Kaghad,M., Wang,Y., Gillett,E., Fleming,M.D., Dotsch,V.,
            Andrews,N.C., Caput,D. and McKeon,F.
  TITLE     p63, a p53 homolog at 3q27-29, encodes multiple products with
            transactivating, death-inducing, and dominant-negative activities
  JOURNAL   Mol. Cell 2 (3), 305-316 (1998)
  MEDLINE   98448095
   PUBMED   9774969
REFERENCE   2  (bases 1 to 835)
  AUTHORS   Hagiwara,K., McMenamin,M.G. and Harris,C.C.
  TITLE     Direct Submission
  JOURNAL   Submitted (29-JAN-1999) Laboratory of Human Carcinogenesis,
            National Cancer Institute, Building 37, Room 2C22, 37 Convent
            Drive, Bethesda, MD 20892, USA
FEATURES             Location/Qualifiers
     source          1. .835
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
     exon            216. .305
                     /gene="P63"
                     /number=1
ORIGIN

  Query Match             8.4%;  Score 499;  DB 9;  Length 835;
  Best Local Similarity   100.0%;  Pred. No. 3.7e-85;
  Matches  499;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       5462 CTGGTAAGAATCGAGTGTTTATGAAGTTTTAGTCAATTGATGAATCTCATTGGCTAAAAT 5521
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 CTGGTAAGAATCGAGTGTTTATGAAGTTTTAGTCAATTGATGAATCTCATTGGCTAAAAT 60

Qy       5522 CAAGAAACGCTCCGCCTCTTTGCAAATATGTATGAAGGAGAGAAGTGCCTAAACTTCTAT 5581
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 CAAGAAACGCTCCGCCTCTTTGCAAATATGTATGAAGGAGAGAAGTGCCTAAACTTCTAT 120

Qy       5582 GTCTGATAGCATTTGACCCTATTGCTTTTAGCCTCCCGGCTTTATATCTATATATACACA 5641
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GTCTGATAGCATTTGACCCTATTGCTTTTAGCCTCCCGGCTTTATATCTATATATACACA 180

Qy       5642 GGTATTTGTGTATATTTTATATAATTGTTCTCCGTTCGTTGATATCAAAGACAGTTGAAG 5701
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GGTATTTGTGTATATTTTATATAATTGTTCTCCGTTCGTTGATATCAAAGACAGTTGAAG 240

Qy       5702 GAAATGAATTTTGAAACTTCACGGTGTGCCACCCTACAGTACTGCCCTGACCCTTACATC 5761
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 GAAATGAATTTTGAAACTTCACGGTGTGCCACCCTACAGTACTGCCCTGACCCTTACATC 300

Qy       5762 CAGCGGTGAGTTTGAATGTGACATAACTTCTCTCAAAACTTAATTGAAGTGCCTTGTGTA 5821
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 CAGCGGTGAGTTTGAATGTGACATAACTTCTCTCAAAACTTAATTGAAGTGCCTTGTGTA 360

Qy       5822 TTATGAATGTGTCAGCTGTGTACAAAGAACAATTCCTCCTTGTTTAGTCAGCACAGTGAT 5881
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TTATGAATGTGTCAGCTGTGTACAAAGAACAATTCCTCCTTGTTTAGTCAGCACAGTGAT 420

Qy       5882 ATTATTTTGGACTTTCTGTGGACTTAAAGTGGTCTGTGGACATATTTTCTGAATGTCTTT 5941
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 ATTATTTTGGACTTTCTGTGGACTTAAAGTGGTCTGTGGACATATTTTCTGAATGTCTTT 480

Qy       5942 TTTGGTTGATATTTGGATC 5960
             |||||||||||||||||||
Db        481 TTTGGTTGATATTTGGATC 499

RESULT 12
```

```
AY339663S1
LOCUS       AY339663S1              531 bp    DNA     linear   PRI 01-SEP-2003
DEFINITION  Homo sapiens P63 protein gene, exon 1 and partial cds,
            alternatively spliced.
ACCESSION   AY339663
VERSION     AY339663.1  GI:34304685
KEYWORDS    .
SEGMENT     1 of 9
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 531)
  AUTHORS   Vieira,A.R. and Murray,J.C.
  TITLE     Sequencing of Candidate Genes for Non-Syndromic Cleft Lip and
            Palate
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 531)
  AUTHORS   Vieira,A.R. and Murray,J.C.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-JUL-2003) Pediatrics, University of Iowa, ML 2182,
            Iowa City, IA 52242, USA
FEATURES             Location/Qualifiers
     source          1. .531
                     /organism="Homo sapiens"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:9606"
                     /chromosome="3"
                     /map="3q27"
     variation       160
                     /replace="t"
     variation       163
                     /replace="c"
     mRNA            <218. .>279
                     /product="P63 protein"
     CDS             218. .>279
                     /note="found in alternatively spliced variants TA alpha,
                     TA beta and TA gamma; alternatively spliced"
                     /codon_start=1
                     /product="P63 protein"
                     /protein_id="AAQ63449.1"
                     /db_xref="GI:34304695"
                     /translation="MNFETSRCATLQYCPDPYIQR"
     exon            <218. .279
                     /number=1
     variation       414
                     /replace="a"
ORIGIN

  Query Match             7.9%;  Score 470.4;  DB 9;  Length 531;
  Best Local Similarity   99.8%;  Pred. No. 1.1e-79;
  Matches  471;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       5489 TTTAGTCAATTGATGAATCTCATTGGCTAAAATCAAGAAACGCTCCGCCTCTTTGCAAAT 5548
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          2 TTTAGTCAATTGATGAATCTCATTGGCTAAAATCAAGAAACGCTCCGCCTCTTTGCAAAT 61

Qy       5549 ATGTATGAAGGAGAGAAGTGCCTAAACTTCTATGTCTGATAGCATTTGACCCTATTGCTT 5608
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         62 ATGTATGAAGGAGAGAAGTGCCTAAACTTCTATGTCTGATAGCATTTGACCCTATTGCTT 121

Qy       5609 TTAGCCTCCCGGCTTTATATCTATATATACACAGGTATTTGTGTATATTTTATATAATTG 5668
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        122 TTAGCCTCCCGGCTTTATATCTATATATACACAGGTATATGTGTATATTTTATATAATTG 181

Qy       5669 TTCTCCGTTCGTTGATATCAAAGACAGTTGAAGGAAATGAATTTTGAAACTTCACGGTGT 5728
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        182 TTCTCCGTTCGTTGATATCAAAGACAGTTGAAGGAAATGAATTTTGAAACTTCACGGTGT 241

Qy       5729 GCCACCCTACAGTACTGCCCTGACCCTTACATCCAGCGGTGAGTTTGAATGTGACATAAC 5788
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        242 GCCACCCTACAGTACTGCCCTGACCCTTACATCCAGCGGTGAGTTTGAATGTGACATAAC 301
```